{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:58:04Z","timestamp":1790683084977,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40272-026-00765-2","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:06:44Z","timestamp":1786079204000},"page":"569-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ocrelizumab: Pediatric First Approval"],"prefix":"10.1007","volume":"28","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"2","key":"765_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40272-024-00675-1","volume":"27","author":"R Suntornlohanakul","year":"2025","unstructured":"Suntornlohanakul R, Yeh EA. Optimizing drug selection in children with multiple sclerosis: what do we know and what remains unanswered? Paediatr Drugs. 2025;27(2):161\u201379.","journal-title":"Paediatr Drugs"},{"issue":"5","key":"765_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2352-4642(24)00047-6","volume":"8","author":"S Sharmin","year":"2024","unstructured":"Sharmin S, Roos I, Malpas CB, et al. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Lancet Child Adolesc Health. 2024;8(5):348\u201357.","journal-title":"Lancet Child Adolesc Health."},{"key":"765_CR3","unstructured":"Genentech, Inc. OCREVUS\u00ae (ocrelizumab) injection, for intravenous use: US prescribing information 2026. https:\/\/www.fda.gov\/. Accessed 13 May 2026."},{"key":"765_CR4","unstructured":"Genentech, Inc. OCREVUSTM (ocrelizumab) injection, for intravenous use: US prescribing information. 2017. https:\/\/www.fda.gov\/. Accessed 15 Jun 2026."},{"key":"765_CR5","unstructured":"Genentech, Inc. FDA approves Genentech\u2019s OCREVUS\u2122 (Ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis [media release]. 28 Mar 2017. https:\/\/www.gene.com\/."},{"key":"765_CR6","unstructured":"Roche Registration GmbH. Ocrevus: EU summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ocrevus. Accessed 15 Jun 2026."},{"key":"765_CR7","unstructured":"Roche. Roche\u2019s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis [media release]. 12 Jan 2018. https:\/\/www.roche.com\/."},{"key":"765_CR8","unstructured":"Genentech, Inc. FDA approves Genentech\u2019s Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis [media release]. 14 Dec 2020. https:\/\/www.gene.com\/."},{"key":"765_CR9","unstructured":"Genentech, Inc. OCREVUS ZUNOVO\u00ae (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use: US prescribing information. 2024. https:\/\/www.fda.gov\/. Accessed 16 Jun 2026."},{"key":"765_CR10","unstructured":"Genentech, Inc. FDA approves Ocrevus Zunovo\u2122 as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis [media release]. 13 Sep 2024. https:\/\/www.gene.com\/."},{"key":"765_CR11","unstructured":"Halozyme Therapeutics, Inc. Halozyme announces Roche's OCREVUS\u00ae SC with ENHANZE\u00ae receives European Commission approval for relapsing and primary progressive multiple sclerosis [media release]. 25 Jun 2024. https:\/\/halozyme.com\/."},{"key":"765_CR12","unstructured":"Genentech, Inc. FDA approves Ocrevus for relapsing-remitting multiple sclerosis in pediatric patients 10 years of age and older [media release]. 8 May 2026. https:\/\/www.gene.com\/."},{"key":"765_CR13","unstructured":"Genentech, Inc. Genentech and IDEC announce humanized anti-CD20 antibody development collaboration [media release]. 20 Jun 2003. https:\/\/www.gene.com\/."},{"key":"765_CR14","unstructured":"Biogen Idec. Biogen Idec and Genentech announce restructuring of anti-CD20 collaboration agreement [media release]. 21 Oct 2010. https:\/\/www.biogen.com\/."},{"issue":"2","key":"765_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12879-z","volume":"272","author":"S Mar","year":"2025","unstructured":"Mar S, Valeriani M, Steinborn B, et al. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025;272(2):137.","journal-title":"J Neurol"},{"issue":"3 Suppl","key":"765_CR16","first-page":"102","volume":"31","author":"E Waubant","year":"2025","unstructured":"Waubant E, Kotulska-Jozwiak K, Valeriani M, et al. Ocrelizumab dose selection for treatment of paediatric relapsing-remitting multiple sclerosis: long-term 96-week safety and efficacy results of the phase II OPERETTA 1 study [abstract no. O106 plus presentation]. Mult Scler J. 2025;31(3 Suppl):102\u20133.","journal-title":"Mult Scler J"},{"key":"765_CR17","unstructured":"Banwell B, Kotulska K, Rost\u00e1sy K, et al. Efficacy and safety of ocrelizumab compared with fingolimod in pediatric-onset relapsing-remitting MS: results of the phase III OPERETTA 2 study [abstract no. 005 plus presentation]. In: 2026 American Academy of Neurology (AAN) Annual Meeting. 2026."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00765-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00765-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00765-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:17:10Z","timestamp":1790680630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00765-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00765-2","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"21 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}